Please login to the form below

Not currently logged in
Email:
Password:

UK launch for gastrointestinal pharma firm

Belgian gastrointestinal pharmaceutical company Movetis has expanded its organisation with the launch of a new UK affiliate

Belgian gastrointestinal (GI) pharmaceutical company Movetis has expanded its organisation with the launch of a new UK affiliate.

Movetis (UK) will focus on the production of novel drugs to be used in the treatment of GI-related diseases where current options are limited.

The UK team includes eight representatives experienced in GI disorders. They will work with a range of products including Resolor (prucalopride), a treatment for chronic constipation in women in whom laxatives fail to provide adequate relief. Resolor was launched in the UK in March, 2010.

The company has said it plans further research involving prucalopride beyond its current indication.

Two products are currently in phase II development for Movetis, with a further two prioritised compounds in preclinical development. All products are aimed at addressing unmet needs in GI treatment.

David Trevor, general manager of Movetis (UK) said "The expansion of the business into the UK is an exciting time for Movetis. As a specialist GI pharmaceutical company we are able to focus our efforts and concentrate on ensuring new treatment options are made available for the management of gastrointestinal disease."

28th July 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics